Nodal Burkitt’S Lymphoma in an AIDS Patient under HAART with a Good Clinical, Immunological and Virological Response

Cárdenas G\textsuperscript{1,2}, Corti M\textsuperscript{1,2,*}, Campitelli A\textsuperscript{3}, Narbaitz M\textsuperscript{4}, Bistman A\textsuperscript{5}

\textsuperscript{1}Division of HIV/AIDS, Infectious Diseases F. J. Muñiz Hospital, \\
\textsuperscript{2}Medicine Department, Infectious Diseases Orientation, University of Buenos Aires, School of Medicine, Buenos Aires, Argentina. \\
\textsuperscript{3}Histopathology Laboratory, F. J. Muñiz Hospital, Buenos Aires, Argentina \\
\textsuperscript{4}National Academy of Medicine, Histopathology Laboratory, Buenos Aires, Argentina \\
\textsuperscript{5}Oncohaematological Section, Ramos Mejía Hospital, Buenos Aires, Argentina

*Corresponding Author: Marcelo Corti, Department of HIV/AIDS, Infectious Diseases F. J. Muñiz Hospital, Puán 381, 2nd Floor, C 1406 CQG, Buenos Aires, Argentina.

Abstract

Non-Hodgkin lymphoma (NHL) of the B-cell type is a frequent complication in HIV-infected patients. The risk to develop NHL is 100 to 200 times higher compared with the general population. The influence of highly active antiretroviral therapy (HAART) on the incidence of some subtypes of AIDS-related lymphomas, including diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL) and plasmablastic lymphoma (PBL) is uncertain and lower with respect to the effect on the develop of opportunistic infections. Generally, NHL is associated with the immunodeficiency related with the retrovirus, but these neoplasms can be seen in patients under HAART with a good clinical, immunological and virological condition. BL has frequently been reported as a neoplasm in HIV infected patients.

Here we present a patient infected with HIV who developed a nodal BL during HAART with immune reconstitution and undetectable viral load. Patient was treated with the same scheme of HAART plus chemotherapy with a prolonged survival and a complete remission of the lymphoproliferative disorder.

Keywords: Non-Hodgkin lymphoma, Burkitt’s lymphoma, HAART, HIV

1. INTRODUCTION

Patients infected with human immunodeficiency virus (HIV) have a high risk to develop non-Hodgkin (NHL) lymphomas. This risk is 100 to 300 times higher in comparison with the general population [1]. Highly active antiretroviral therapy (HAART) reduce the incidence of some subtypes of NHL, especially, primary central nervous system lymphoma (PCNSL), but the influence on other subtypes of lymphoma, including diffuse large B cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), plasmablastic lymphoma (PBL) and Hodgkin’s disease (HD) is uncertain.

Here, we describe an HIV-infected patient under HAART, with a good clinical, immunological and virological response, who developed a nodal BL, successfully treated with chemotherapy plus HAART.

2. CASE REPORT

A 36 year-old man, with recent diagnosis of HIV infection started treatment on HAART with plasma viral load of 77 900 copies/mL and CD4-T cell count of 422 cell/µL (16%).

He was negative for syphilis, HCV, HBV, Toxoplasma gondii and Trypanosoma cruzi antibodies. Routine laboratory analysis was normal. In this setting, he started HAART based on tenofovir, emtricitabine, darunavir/ritonavir, QD, with a good adherence and tolerance. Two months later, he consulted due to the appearance of a large tumor lesion located in the right submaxillary region without other symptoms (figure 1).
Systemic examination was normal; the blood tests revealed hemoglobin of 13g/dL, WBC 8700/mL (43% of neutrophils and 42% of lymphocytes) and 275000 platelets/mm3. Renal and liver functions were normal. Lactate deshidrogenase (LDH) was elevated 647 UI/mL. The plasma viral load was undetectable (< 40 copies/mL) and the CD4-T-cell count of 387 cell/µL. A computed tomography (CT) scan of the head and neck was made and showed a large, heterogeneous adenomegaly of 5.3 mm of transverse diameter located below the dental arch (figure 2).

An excisional biopsy was done; histopathological examination of biopsy smears revealed a diffuse monotonous infiltrate of medium to large-sized monomorphic cells with round nuclei, multiple nucleoli and scarce basophilic cytoplasm. The nuclei are round with clumped chromatin and contain multiple basophilic nucleoli. Scattered macrophages, impart the image of “scary sky pattern” (figure 3).

The atypical cells expressed CD20, CD10 and BCL6. Ki67 antigen was > 98%. A CT scan of brain, thorax, abdomen and pelvis showed no evidence of neoplasm. The bone marrow biopsy was negative to atypical cell infiltration and a lumbar puncture was also negative for neoplastic cells. Final diagnosis was BL stage I. Patient was started on chemotherapy plus the same scheme of HAART. He received CODOX-M (cyclophosphamide, doxorubicin, vincristine with intrathecal methotrexate and cytarabine followed by high-dose of systemic methotrexate) e IVAC (ifosfamide, cytarabine, etoposide and intrathecal methotrexate) which was associated with a good clinical, immunological and virological response (figure 4). Two years after diagnosis of BL he is in a good clinical condition.

3. DISCUSSION

NHL is a heterogeneous group of malignancies that, in HIV seropositive patients, are of B phenotype and high grade. Also, generally, AIDS-associated NHL are diagnosed in advanced stages of the neoplasm diseases and with frequent extranodal locations as primary
manifestation of the disease [2]. Actually, the best treatment of NHL in AIDS patients is based on the combination of HAART plus chemotherapy [3, 4].

In HIV/AIDS patients, BL account for about 35% to 40% of all NHL in comparison with 1% to 2% in the general population. The HIV infection is an infection that should be ruled out in cases of BL [5]. BL is an aggressive B-cell lymphoma with three clinical forms: endemic BL, usually associated with Epstein-Barr virus (EBV) in his pathogenesis; sporadic variant, less related to EBV infection and immunodeficiency or immunosuppression associated BL, that is seen especially in HIV-seropositive patients [6]. BL in HIV patients is strongly associated with the EBV in his pathogenesis [7]. EBV was the first human tumor virus described in 1970; the virus genome is identified in the atypical tumor cells of BL and other lymphoid neoplasm. In consequence, DNA sequences of this virus may be found in B cells and elevated titers of anti-EBV antibodies are detected in patients with BL [8]. Treatment of BL is similar to other aggressive lymphomas; the Magrath regimen, used in the described patient, include the CODOX-M (cyclophosphamide, doxorubicin, vincristine with intrathecal methotrexate and cytarabine followed by high-dose of systemic methotrexate) e IVAC (ifosfamide, cytarabine, etoposide and intrathecal methotrexate) has been associated with a good clinical response [9, 10]. The CODOX-M/IVAC regimen was developed by Magrath et al and showed a similar and excellent rate of response in adults with BL. CODOX-M/IVAC is a short regimen associated with high cure rates of nearly 90% [11].

The survival of patients with AIDS-related NHL is significantly longer compared with the pre-HAART era, with high rates of complete remission and prolonged response to HAART, as we can see in our patient [12, 13]. Prolonged survival is significantly associated with achievement of a complete remission and a good virological response to HAART [14]. In comparison with a median survival of 7 months after NHL diagnosis in the pre-HAART era, the survival is prolonged in the post-HAART period [12, 13, 15].

4. Conclusion

The association of HAART and chemotherapy is safety and effective, improving the clinical response rate and the prognosis of this kind of patients [3, 16].

REFERENCES

Nodal Burkitt’S Lymphoma in an AIDS Patient under HAART with a Good Clinical, Immunological and Virological Response


Copyright: © 2020 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.